Navigation Links
Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. Patients received blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients received a continuous intravenous infusion of blinatumomab at an initial dose of five or 15 micrograms/m2 per day, escalating to 30 micrograms for the remainder of the treatment. The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh*). Secondary endpoints included molecular response rate, duration of response and overall survival. All 36 patients were evaluable for efficacy and safety.

Twenty-six of the 36 patients (72%) treated with blinatumomab across all of the tested doses and schedules achieved a CR/CRh*. All but two patients achieved a molecular response, meaning there was no evidence of leukemic cells by polymerase chain reaction. The most common adverse events were pyrexia, headache and tremor. Medically important safety events were reversible cytokine release syndrome and CNS adverse events.

At the time of the analysis, median survival was 9.0 (8.2, 15.8) months with a median follow-up period of 10.7 months. The median duration of response in the 26 patients who responded to treatment was 8.9 months.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
8. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
9. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. GeneLink Reports First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and ... candidates to participate in an investigational study of donor ... goal of this study is to determine if a ... two arthritically affected joints can help reduce pain and ... the current investigational study must be older than nine ...
(Date:8/29/2014)... MA (PRWEB) August 29, 2014 A ... in the biotech start-up dense realm of Boston-Cambridge, is ... and able investors. James Sherley, the Director of Boston’s ... increasing the local and national visibility of his company ... September 2013. , In addition to a social media ...
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... Sept. 30 DOR BioPharma, Inc. (OTC Bulletin Board: SNGX), ... a corporate name change from DOR BioPharma, Inc. to Soligenix, ... name change, the Company,s shares of common stock will immediately ... today. , "We are pleased to announce the ...
... 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ... and commercializing products for the treatment of cancer, ... of late-stage immunotherapy product candidates from Paladin Labs ... candidates consists of five monoclonal antibodies targeting certain ...
... , ... application enables system access and security for federal employees, regardless of location , ... Miami, FL (PRWEB) September ... landmark partnership with the Ministry of Health in Spain, providing the agency with software-based ...
Cached Biology Technology:DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 2Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 3Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 4Spain's Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 2Spain's Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 3
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... 2014, 10:20 AM EDT) It may be possible ... over unhealthy higher-calorie foods, according to new research by ... Center on Aging (USDA HNRCA) at Tufts University and ... journal Nutrition & Diabetes , a brain scan ... is possible to reverse the addictive power of unhealthy ...
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
Breaking Biology News(10 mins):Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
... microbe samples while preserving the microbes, natural gene expression ... varieties of small RNAs snippets of RNA that ... single-celled creatures. Before now, small RNA could only be ... in a natural setting may make it possible finally ...
... Jersey Chapter of the American Society of Civil Engineers ... to John Schuring, Stabile Professor for Innovation and Technology ... expert, contact Sheryl Weinstein at 973-596-3436.) Schuring, ... has 35 years of experience in the areas of ...
... Jersey Chapter of the American Society of Civil Engineers ... to John Schuring, Stabile Professor for Innovation and Technology ... expert, contact Sheryl Weinstein at 973-596-3436.) Schuring, ... has 35 years of experience in the areas of ...
Cached Biology News:MIT reels in RNA surprise with microbial ocean catch 2MIT reels in RNA surprise with microbial ocean catch 3Civil engineers name NJIT's John Schuring Educator of Year 2Civil engineers name NJIT's John Schuring Educator of Year Award 2
MOUSE ANTI RAT RT1Bu Immunogen: Rat thymocyte membrane glycoproteins...
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
... (CMV) pp65 Antigenemia Immunofluorescence Assay (IFA) is ... matrix protein pp65 of CMV in isolated ... Erythrocyte Lysis Buffer - ... mL of buffered ammonium chloride. (NH4CL) ...
Biology Products: